Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Monoclonal antibody for detecting novel coronavirus and application of preparation kit

A monoclonal antibody, coronavirus technology, applied in biological testing, antiviral immunoglobulin, applications, etc., can solve the problems of lack of antibody duration, systematic research, etc., to achieve high specificity, broad market prospects, titer high effect

Active Publication Date: 2020-06-12
BEIJING SUNGEN BIOMEDICAL TECH CO LTD
View PDF1 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is still a lack of systematic research on the production and duration of these two types of antibodies against the new coronavirus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody for detecting novel coronavirus and application of preparation kit
  • Monoclonal antibody for detecting novel coronavirus and application of preparation kit
  • Monoclonal antibody for detecting novel coronavirus and application of preparation kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] The epitope optimization of embodiment 1N protein

[0028] According to the published whole genome sequence of 2019-nCoV, an optimized N protein epitope amino acid sequence was designed for the N protein amino acid sequence peptide. Through Clustal W (Version1.81) software multiple sequence comparison of 5 amino acid sequences of different strains such as Chinese strain and Italian strain, the sequence was analyzed, and the immunogenicity, hydrophilicity, surface possibility and related secondary structure were analyzed according to DNAstar . Through Modeller homology modeling, the three-dimensional structure of the protein was constructed, and the surface possibility of the immunogenic polypeptide was further analyzed. The antibody-binding epitope peptide was simulated by the MOE software, and the interacting amino acids were analyzed, and the N protein sequence with good immunogenicity was screened. , and from Figure 1A and Figure 1B In comparison, Figure 1B Th...

Embodiment 2

[0034] Expression of embodiment 2N protein

[0035] Design specific primers according to the optimized N protein nucleotide sequence, respectively add protective bases and restriction endonucleases at the 5' end of the primers, and the primer sequences are as follows:

[0036] F:5'-CGC GGATCC ATGAAAGACCTGTCTCCGCG-3' (SEQ. ID. NO. 3):

[0037] R:5'-CCG GAATTC GTCGTCCAGTTTGATAGCAC-3' (SEQ.ID.NO.4):

[0038] Using the optimized N protein gene synthesized by the whole gene as a template (Shanghai Sangong Synthetic), PCR amplification was carried out with the above-mentioned specific primers.

[0039] The PCR reaction program was: pre-denaturation at 94°C for 2 min; denaturation at 94°C for 10 sec, annealing at 55°C for 35 sec, extension at 67°C for 1 min and 10 s, 35 cycles; extension at 68°C for 7 min, and storage at 4°C.

[0040] PCR reaction system: 2×PCR Buffer 12.5μL, 2mM dNTPs 5μL, 10mM R Primer 0.75μL, 10mM F Primer 0.75μL, N DNA 1μL, dHO 2 O 5 μL.

[0041] The ampl...

Embodiment 3

[0044] The preparation of embodiment 3 monoclonal antibody

[0045] Fifteen Balb-c mice, female, 8 weeks old, with a body mass of (20±2) g, were provided by the Experimental Animal Center of Yangzhou University. Randomly divided into 3 groups, 5 in each group. Take the N protein obtained in Example 2 as the immunogen, fully emulsify it with an equal amount of complete Freund's adjuvant, inject the antigen at multiple points subcutaneously in mice at an amount of 70 μg / mouse, and emulsify the antigen with incomplete Freund's adjuvant 2 weeks later The second immunization was carried out, and after the third immunization, the ELISA titer was detected to be >1:10,000, and 50 g of antigen was used for intraperitoneal impact immunization, and fusion was performed 3 to 4 days later.

[0046] Aseptically take the spleen of the mouse, prepare splenocytes, and fuse the splenocytes with myeloma SP2 / O cells in the logarithmic growth phase with a volume fraction of 50% PEG4000; the fused...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a monoclonal antibody for detecting a novel coronavirus and an application of a preparation kit. An N protein is an important marker protein of coronavirus, and coronavirus detection can be realized by detecting the N protein. An anti-N protein monoclonal antibody obtained in the invention has characteristics of high specificity and mass production, and a titer of the obtained antibody is relatively high. The anti-N protein monoclonal antibody obtained in the invention can be specifically combined with the N protein, can be used for immunological detection of cells, has a wide market prospect and has important clinical significance.

Description

technical field [0001] The invention belongs to the field of biological detection, in particular to a monoclonal antibody for detecting novel coronavirus and its preparation kit. Background technique [0002] Common signs after a person is infected with a coronavirus include respiratory symptoms, fever, cough, shortness of breath, and dyspnea. In more severe cases, infection can lead to pneumonia, severe acute respiratory syndrome, kidney failure, and even death. Although there is currently no specific treatment for the disease caused by the new coronavirus, the treatment of mild or asymptomatic patients can greatly improve the cure rate and shorten the treatment time. Therefore, it is particularly important to detect or identify patients. [0003] Rapid and accurate diagnosis of infectious diseases is a key factor in controlling disease outbreaks. As the number of people infected with the novel coronavirus (2019-nCoV) continues to increase, many in vitro diagnostic compa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/40G01N33/68G01N33/577G01N33/569
CPCC07K16/10G01N33/56983G01N33/577G01N33/68G01N2333/165
Inventor 彭菲陈印平
Owner BEIJING SUNGEN BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com